Partner Nate Lacktman was quoted in an mHealthIntelligence article, “OIG: HIV Telemedicine Program Doesn’t Violate Anti-Kickback Laws,” about a ruling by federal regulators that a health care provider’s plan to offer free telemedicine technology to a county-run HIV-care clinic doesn’t run afoul of anti-kickback laws.
Lacktman said the decision mirrors an earlier ruling by the OIC in which a health system gave free telemedicine equipment to certain community hospitals to establish a telestroke network. The latest decision “focused on how the specific terms of the arrangement include a number of safeguards to reduce the risk of patient steering and kickbacks, notwithstanding the fact that the provider would give free telemedicine technology to the county health clinic,” he said.
Lacktman said the decision mirrors an earlier ruling by the OIC in which a health system gave free telemedicine equipment to certain community hospitals to establish a telestroke network. The latest decision “focused on how the specific terms of the arrangement include a number of safeguards to reduce the risk of patient steering and kickbacks, notwithstanding the fact that the provider would give free telemedicine technology to the county health clinic,” he said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."